Hasil Pencarian  ::  Simpan CSV :: Kembali

"Merokok dapat meningkatkan angka morbiditas dan mortalitas.World Health Organization (WHO) memprediksi pada tahun 2020 penyakit yang disebabkan oleh rokok akan menyebabkan kematian sebanyak 8.4 juta orang di dunia dan setengahnya berasal dari Asia. Varenicline, sebagai agonis parsial reseptor α4β2 nikotin asetilkolin, memiliki potensi yang cukup baik pada program berhenti merokok dengan cara melepaskan withdrawal effect dari nikotin dan menurunkan kebutuhan akan nikotin. METODE. Uji acak tersamar ganda antara bulan Juli 2012 sampai dengan Desember 2012 dengan 12 minggu waktu terapi dan 12 minggu waktu pengamatan status merokok. 80 laki-laki perokok yang bersedia mengikuti penelitian dibagi kedalam kelompok varenciline dan kelompok plasebo.Varenicline dititrasi hingga 2x1 mg (n=40) dan plasebo (n=40) ditambah konseling mingguan. HASIL. Pada pengamatan 4 minggu (minggu 1-4) setelah 12 minggu terapi menunjukkan 55% peserta kelompok varenicline berhenti merokok dibandingkan kelompok plasebo sebesar 27,5%. (Prevalence Ratio [PR] 2,0). Pada pengamatan minggu ke 5-8, 52.5% peserta pada kelompok varenicline masih berhenti merokok dibandingkan dengan 20% pada kelompok plasebo (PR, 2,6). Pada pengamatan minggu 9-12, 47,5% peserta pada kelompok varenicline masih berhenti merokok dibandingkan 17,5% pada kelompok plasebo (PR, 2,7). Rerata hari pertama bebas rokok pada kelompok varenicline adalah 40,63 hari, sedangkan pada kelompok plasebo 56,43 hari. Efek samping yang paling banyak pada penggunaan varenicline adalah mual yang terdapat pada 9 peseerta (22,5%). Rerata kadar CO awal adalah 18,46 ppm, rerata Fagerstrom test untuk ketergantungan nikotin adalah 6,4 dan rerata indeks Binkman adalah 317,9. KESIMPULAN. Varenicline memiliki efikasi yang baik, aman dan dapat ditoleransi baik sebagai farmakoterapi program berhenti merokok.

---

Smoking has increased risk of morbidity and mortality. World Health Organization predicts that by 2020, disease caused by smoking will result in the deaths of around 8.4 million people in the world and half of these deaths from Asia. Varenicline, a partial agonist at the α4β2 nicotinic acetylcholine receptor, has the potential to aid smoking cessation by relieving nicotine withdrawal symptoms and reducing the rewarding properties of nicotine.

METHOD. A randomized, single-blind, placebo controlled trial conducted between July 2012 and December 2012 with a 12 week treatment period and 12 week follow-up of smoking status. 80 male adult smokers who volunteered for the study divide into varenicline and placebo group. Varenicline titrated to 1 mg twice daily (n=40) or placebo (n=40) for 12 weeks, plus weekly smoking cessation counseling.

RESULT. During 4 weeks (weeks 1-4) after 12 weeks of treatment, 55% of participants in the varenicline group were continuously abstinent from smoking compared with 27.5% in the placebo group (Prevalence Ratio [PR] 2,0). For weeks 5 through 8, 52.5% of participants in the varenicline group were continuously abstinent compared with 20% in the placebo group (PR, 2,6). For weeks 9-12, 47.5% of participants in the varenicline group were continuously abstinent compared with 17.5% in the placebo group (PR, 2,7). Mean of first day free of smoking used Varenicline for smoking cessation was 40,63 days and mean of first day free of smoking used placebo was 56.43 days. The most adverse event with varenicline was nausea, which occurred in 9 Participants (22,5%). Mean of CO level was 18,46 ppm, mean of Fagerstrom score for nicotine dependence was 6,4, and mean of Brinkman index was 317,9.

CONCLUSION. Varenicline is an efficacious, safe, and well-tolerated smoking cessation pharmacotherapy."

"Penelitian ini mencari perbedaan rata-rata motivasi berhenti merokok pada mahasiswa UI di antara kelompok responden berdasarkan akses terhadap rokok yang paling sering digunakan. Penelitian ini menggunakan metode cross-sectional dengan teknik menggunakan kuesioner. Nilai rata-rata motivasi berhenti merokok dari dalam diri responden (n=96) adalah 4,43 dari skor maksimal 7. Nilai rata-rata motivasi berhenti merokok dari luar diri responden adalah 3,31 dari skor maksimal 7. Lima puluh delapan dari 96 responden (60,4%) menyatakan membeli di warung sebagai akses terhadap rokok yang paling sering digunakan. Analisis Anova menunjukkan tidak terdapat perbedaan rata-rata motivasi berhenti merokok dari diri sendiri yang bermakna di antara kelompok responden berdasarkan akses tersering membeli di warung, membeli di swalayan, dan mendapat dari keluarga dan kerabat (CI= 95%, P= 0,88), maupun antara motivasi berhenti merokok dari luar diri di antara kelompok responden berdasarkan akses tersering membeli di warung, membeli swalayan, dan mendapat dari keluarga dan kerabat (CI= 95%, P= 0,28). Hasil ini menunjukkan bahwa faktor yang lebih berpengaruh kepada motivasi berhenti merokok seseorang adalah faktor dari dalam diri sendiri dibandingkan dari luar diri. Sebaiknya dilakukan penelitian mengenai faktor dari dalam diri untuk meneliti motivasi berhenti merokok karena didapatkan bahwa faktor dari dalam diri lebih berperan dalam hal ini.

---

This study aims to seek out the means difference in smoking cessation motivation among Universitas Indonesia students among respondent based on their access to cigarette. The method of this research is cross-sectional with questionnaire as the data-gathering means. The means of smoking cessation motivation because of internal factors of the respondents (n=96) is 4.43 out of 7. The means of smoking cessation motivation because of external factors of the respondents is 3.31 out of 7. Fifty eight respondents out of 96 respondents (60.4%) stated that buying cigarette in stalls is the most frequently used access to cigarette.

Anova analysis shows that there is no significant difference in smoking cessation motivation from internal factors means between groups that use buying cigarette in stalls, buying from self-service shop, or receiving cigarette from family and fellows (P= 0.878). Anova analysis also shows shows that there is no significant difference in smoking cessation motivation from external factors means between groups that use buying cigarette in stalls, buying from self-service shop, or receiving cigarette from family and fellows (P = 0.28).

This results indicates that smoking cessation motivation is more affected by internal factors than external factors. It is better to make a research for internal factors that affect smoking cessation motivation in the future because internal factors are more govern to smoking cessation motivation."

"Pengantar: Batu saluran kencing adalah salah satu penyebab yang paling sering dari nyeri kolik yang muncul pada layanan kesehatan primer. Penanganan dari kasus batu saluran kemih dibagi menjadi beberapa kelompok yaitu operatif dan juga konservatif. Cystone adalah salah satu terapi tambahan yang dapat ditambahkan pada regimen penanganan konservatif untuk ukuran batu dan memudahkan pengeluaran batu saluran kemih. Penelitian ini bertujuan untuk melihat keamanan dan efektivitas dari pemberian Cystone ini pasca tindakan ESWL. Metodologi : Penelitian ini dilakukan antara bulan Mei 2014-November 2015, jumlah sampel yang berpartisipasi dalam penelitian ini adalah 81 sampel, 42 berada pada grup cystone dan 39 dalam grup placebo. Setelah dilakukan ESWL, satu grup diberikan tablet cystone 2 x 2 setiap hari selama 4 minggu, grup lain diberikan placebo. Penanganan lanjutan seperti KUB radiografi, CT urografi dan juga pemeriksaan USG dilakukan setelah mengkonsumsi obat-obatan ini.Hasil: Dari 84 sampel yang berpartisipasi dalam penelitian ini, karkteristik demografik dan baseline antara grup tatalaksana dan grup placebo mirip satu sama lain. Tidak ada perbedaan statistic yang signifikan antara besar batu sebelum dan sesudah konsumsi cystone baik pada grup cystone ataupun placebo. Satu kejadian efek samping yang serius dilaporkan pada grup cystone, tidak ada kejadian efek samping yang berat terlihat pada grup placebo. Diskusi: Penelitian sebelumnya memperlihatkan bahwa cystone ini secara signifikan dapat memperkecil besar batu ginjal dan mengubah komposisi batu ginjal. Hasil yang berbeda ini kemungkinan disebabkan oleh perbedaan besar batu ginjal baik pada riset ini maupun literature-literatur sebelumnya. Berdasarkan penelitian ini, kami tidak merekomendasikan penggunaan cystone sebagai terapi adjunctive- management conservative dari batu ginjal ini.

---

Introduction: Urinary stone is one of the most common cause of colicky pain in primary care. Management of urinary stone is divided into operative management and conservative management. Cystone is one of the traditional adjunctive therapy that may added to conservative management regiment to reduce kidney stone size and speed-up the stone passing. This study aims to see the efficacy and safety of Cystone after Extracorporeal Shock Wave Lithotripsy. Methods : This clinical trial was conducted from May 2014-November 2015, the total sample for this research are 81 samples, 42 in cystone group and 39 in placebo group. After undergoing ESWL procedure, one group were given 2 x 2 cystone tables daily for 4 weeks, and the other were given placebo. Further examination such as KUB radiography, CT urography, USG examination were conducted after consumption of the drugs. Results : Among 84 subjects that participated in this research, demographic charcteristics and baseline disease were comparable. No statistically significant changes on the stone size in both cystone and placebo group. One serious adverse event appeared in cystone group compared to none in the placebo group. Discussion: Previous research showed that cystone made significant changes on the renal stone size and composition. This differing results may be caused by different stone sizes in both this research and previous literature. Based on this research’s result we do not recommend using cystone as an adjunctive conservative management of renal stone"

"Nowadays, many children in developing countries are suffering from micro nutrient deficiencies (Lartey et at., 2000b; Zhao et al., 1998; van Stuijvenberg et al, 1999; Sempertegui et at, 1995). And the most prevalent ones are VAD (Vitamin A Deficiency), IDA (Iron Deficiency Anemia), IDD (Iodine Deficiency Disorder), and lately is zinc deficiency (Sandstead, 1991).The causes of micro nutrient deficiencies are varied and include inadequate dietary intakes (Robert et al, 2000), repeated infections (Khanum et al, 1998) and poor bioavailability from foods due to the presence of inhibitors or inadequate intake of dietary enhancers (Berdanier, 1998; Lunnerdal, 2000; de Pee et al, 1998; Donnen et al, 1996; Lartey et al, 2000a).Due to the roles of micronutrients in metabolic process, immune competence and taste acuity (Golden, 1995), previous findings showed that micronutrient deficiencies might impaired growth (Allen, 1994b; Rosado, 1999; Krieger et al, 1986; Simondon et al, 1996; Hambidge, 2000; Golden & Golden, 1981) and immune system (Black, 1998; Khanum et al, 1998; Semba et al, 1993). The reversibility of impairments caused by micronutrient deficiencies depends on the severity, duration, and stage of development. In some cases, micronutrient supplementation can correct the impairment right after a certain period of supplementation. Ninh et al (1996) stated that zinc deficiency among nutritionally deprived children may limit growth because the growth stimulating effects of zinc might be mediated through changes in circulating insulin-like growth factor (IGF). And after 5 months supplementation with daily-10 mg zinc, weight and height of growth-retarded children in supplemented group significantly increased compared to those of placebo group. In Uganda, zinc supplementation had a short-term effect (within 3 months) on weight gain and MUAC increment only among children from the school with the highest socioeconomic status (Kikafunda et al, 1998). Clinical vitamin A deficiency has been associated with poor child growth (Tarwotjo et al, 1992). Study in Zaire among moderately malnourished preschoolers found that high dose vitamin A supplementation (60 mg of oily solution of retinal palmitate, 30 mg if aged <12 months) increased MUAC and weight significantly compared to control group although without deforming at baseline (Donnen et al, 1998). In Indonesia, the intervention using vitamin A-monosodium glutamate did not merely result on increment of serum vitamin A level, but it also increased the linear growth of supplemented children compared to children in control group at every age (Muhilal et al, 1988). Similar with zinc and vitamin A, iron deficiency may also lead to slowing of growth in regarding to the increment of iron demands during periods of rapid growth and the adverse effects of morbidity. "

"Rhinos® SR adalah kapsul kombinasi tetap loratadin 5 mg dengan pseudoefedrin 60 mg lepas cepat dan pseudoefedrin 60 mg lepas lambat. Studi ini bertujuan untuk menilai efikasi Rhinos® SR pada nasal airway resistance (NAR) secara obyektif dengan rhinomanometer dan gejala-gejala nasal serta nonnasal pada pasien dengan rinitis alergik sepanjang tahun (RAST) di negara tropis. Ini adalah studi paralel berpembanding plasebo, acak, tersamar ganda, dilakukan pada 59 pasien RAST berobat jalan di klinik THT RS Umum Dr. Soetomo, Surabaya. Pasien laki-laki dan perempuan, menderita RAST sedang sampai berat minimal 2 tahun, berumur 12 tahun ke atas, dengan total skor gejala nasal (TSGN) > 6 dan skor kongesti nasal (SKN) > 2, mendapat Rhinos® SR atau plasebo 2 kali sehari selama 7 hari. Parameter efikasi yang utama adalah berkurangnya nilai-nilai NAR (yang diukur dengan rhinomanometer pada hari pertama) dari Rhinos® SR dibandingkan dengan plasebo. Nilai-nilai NAR dihitung sebagai luas area di bawah kurva (area under the curve = AUC) dari NAR terhadap waktu. Parameter efikasi sekunder adalah berkurangnya gejala-gejala klinik (nasal dan nonnasal) yang dinilai oleh pasien maupun oleh dokter peneliti setelah 1 minggu penggunaan Rhinos® SR atau plasebo. Dari 59 pasien yang memenuhi syarat, semuanya menyelesaikan studi 1 minggu ini. Untuk nilai-nilai NAR, setelah baseline disamakan menjadi 100%, AUC0-10 jam tidak berbeda bermakna antara Rhinos® SR dan plasebo. Akan tetapi waktu pseudoefedrin mencapai kadar puncak, yakni 2 jam untuk yang lepas cepat dan 6 jam untuk yang lepas lambat, maka AUC0-2 jam dan AUC0-6 jam Rhinos® SR lebih rendah secara bermakna dibandingkan dengan plasebo. TSGN berdasarkan penilaian penderita (jumlah skor 3 pagi terakhir) untuk Rhinos® SR menurun 33.0% dari skor awal (p < 0.001), untuk plasebo juga menurun 21.9% dari skor awal (p = 0.002), tetapi penurunan oleh Rhinos tidak berbeda bermakna dengan penurunan oleh plasebo. Penurunan TSGN berdasarkan penilaian dokter peneliti, serta penurunan skor kongesti nasal (SKN) dan total skor gejala (nasal dan nonnasal), dan bahkan skor masing-masing gejala, berdasarkan penilaian pasien maupun dokter peneliti, menunjukkan pola yang sama, yakni Rhinos® SR dan plasebo menurunkan gejala secara bermakna dari nilai awal, dan penurunan oleh Rhinos® SR lebih besar dibandingkan penurunan oleh plasebo tetapi tidak berbeda bermakna. Dalam studi ini tidak ditemukan efek samping. Dari penelitian ini disimpulkan bahwa pada pasien RAST sedang sampai berat di negara tropis, Rhinos® SR efektif dalam mengurangi kongesti nasal dengan pengukuran obyektf NAR. Rhinos® SR 2 x sehari selama 7 hari juga efektif dalam mengurangi gejala-gejala klinik RAST meskipun tidak mencapai kemaknaan statistik dibandingkan dengan plasebo, serta dapat ditoleransi dengan baik.

---

AbstractRhinos® SR is a fixed combination of 5 mg loratadine and 60 mg pseudoephedrine immediate release and 60 mg pseudoephedrine sustained release. The present study was aimed to assess the efficacy of Rhinos® SR on nasal airway resistance (NAR) objectively using rhinomanometer and on nasal symptoms in patients with perennial allergic rhinitis (PAR) in a tropical country. This was a randomized, double-blind, parallel group study in 59 PAR patients who visited the ENT clinic at Dr. Soetomo General Hospital, Surabaya. Outpatients of both gender, having moderate to severe PAR for a minimal of 2 years, aged 12 years or older, with a total nasal symptom score (TNSS) > 6 and a nasal congestion score > 2, received Rhinos® SR or placebo twice daily for 7 days. The primary efficacy parameter was the decrease in the NAR values (measured by rhinomanometer on Day 1) of Rhinos® SR from those of placebo. The NAR values were calculated as the area under the curve (AUC) of NAR versus time. The secondary efficacy parameters were the percentage reduction of the clinical symptoms (nasal and nonnasal) evaluated by both the patient and the physician after 1 week use of Rhinos® SR or placebo. From 59 eligible patients, all completed this 1-week trial. For NAR values, after the baseline were considered as 100%, the AUC0-10 h were not significantly different between Rhinos® SR and placebo. However, as the pseudoephedrine reached its peak concentration, i.e. 2 hrs for the immediate release and 6 hrs for the sustained release, then AUC0-2 h and AUC0-6 h of Rhinos® SR were significantly lower compared to those of placebo. Total nasal symptom score (TNSS) evaluated by the patient (sum of the last 3 mornings) for Rhinos® SR decreased 33.0% from baseline (p < 0.001), for placebo decreased 21.9% from baseline (p = 0.002), but the decrease by Rhinos® SR was not significantly different from the decrease by placebo. TNSS evaluated by the physician, nasal congestion score (NCS) and total symptom score (TSS, total nasal and nonnasal), and even the individual symptom scores, evaluated by the patient and the physician, showed similar pattern, i.e. both Rhinos® SR and placebo decreased the symptoms significantly from baseline, and the decreases by Rhinos® SR were larger than the decreases by placebo, but the decreases by Rhinos® SR and placebo were not statistically different. No adverse event was found in this study. From the present study it was concluded that in patients with moderate to severe PAR in a tropical country, Rhinos® SR was effective in relieving nasal congestion by objective measurements of NAR. Rhinos® SR twice a day for 7 days was also effective in reducing the clinical symptoms of PAR although the reductions did not reach statistical significance compared to those by placebo, and was well tolerated. "

"Tesis ini membahas tentang bagaimana hubungan pengetahuan dan sikap dengan niat melaksanakan konseling berhenti merokok di antara mahasiswa profesi dan spesialis kedokteran gigi di RSKGM FKG UI. Penelitian ini adalah penelitian kuantitatif dengan desain potong lintang. Sikap merupakan variabel yang paling besar mempengaruhi niat melakukan konseling berhenti merokok, setelah dikontrol oleh variabel umur, jenis kelamin, pendidikan, status merokok, dan pengetahuan. Nilai OR (OR adjusted) = 59,795 (95% CI 14,777-241,957). Hasil penelitian ini menyarankan agar ada upaya pembentukan sikap terhadap perilaku konseling berhenti merokok melalui pendidikan yang terencana, terarah, dan berkesinambungan.

---

This thesis discusses how the relationship between knowledge and attitudes with the intention of implementing smoking cessation counseling among students of professional and specialist dentistry in RSKGM FKG UI. This research is a quantitative study with a cross-sectional design. Attitude is the biggest variable affecting intention to quit smoking counseling, once controlled by the variables of age, gender, education, smoking status, and knowledge. OR value (OR adjusted) = 59.795 (95% CI 14.777 to 241.957). The results of this study suggest that there are efforts to establish attitudes towards smoking cessation counseling behaviors through education planned, directed, and continuous."

"Background: the use of statin to lower blood cholesterol is often associated with bothersome adverse effects such as myopathy and liver dysfunction. NC120 is herbal lipid lowering drug containing red yeast rice (RYR) extract, guggulipid, and chromium picolinate, and expected to have better safety profile. The aim of this study was to evaluate the efficacy and safety profiles of NC120 in lowering blood lipid. Methods: this was a double blind randomized clinical trial comparing NC120 with placebo in subjects with hypercholesterolemia. Two capsules of NC120 or placebo were administered twice a day for 28 days. Blood total-cholesterol, LDL-cholesterol, and triglyceride were measured on day-0, day-7, and day-28. Unpaired t-test was used to compare study parameter between groups, and one-way ANOVA was used to compare within group. Results: 25 subjects received NC120 and 24 subjects received placebo. Significant decrease of total cholesterol and LDL-cholesterol were observed since day-7 in NC120 group, while the changes in placebo group were not significant at all time of observation. No significant decrease of triglyceride was observed in NC120 group and in placebo group. Side effects were minor and comparable between the two groups. Conclusion: NC120 is effective in reducing total cholesterol and LDL-cholesterol, but not triglyceride. This drug shows a good safety profile, and thus can be considered for patients who can not tolerate statin drugs."

"Penelitian ini bertujuan untuk mengetahui keterjadian flypaper effect dan pengaruh faktor politik pada belanja hibah. Flypaper effect terjadi saat pengaruh DAU lebih besar dari pengaruh PAD terhadap belanja daerah. Faktor politik terdiri dari dua faktor, yaitu siklus politik yang diproksikan oleh tahun pemilu dan konsentrasi politik diproksikan oleh indeks konsentrasi politik. Sampel penelitian terdiri dari 33 Pemerintah Provinsi di Indonesia tahun 2011-2015. Pengujian hipotesis dilakukan menggunakan regresi data panel random effect model untuk mendapatkan model terbaik. Hasil penelitian menunjukkan bahwa flypaper effect tidak terjadi pada belanja hibah. Tahun pemilu signifikan terhadap belanja hibah dimana belanja tersebut akan meningkat pada tahun diadakannya pemilu. Konsentrasi politik signifikan untuk belanja hibah, semakin rendah konsentrasi politik, belanja hibah semakin tinggi. Dapat disimpulkan bahwa flypaper effect mendapatkan stimulus tambahan saat tahun pemilu, sedangkan konsentrasi pada dewan dengan konsentrasi politik rendah, belanja hibah akan semakin tinggi.

---

The aims of this research are to determine the occurrence of flypaper effect and the effect of political factors in grant expenditures. Political factors consist of two variables, first is political cycle which is proxied by electoral years and second is political concentration proxied by political concentration index. The sample in this study consisted of 33 Provincial Governments in Indonesia during 2011-2015. Hypothesis testing is perform with panel data regression with random effect model to gather the best fitting model. The research reveals that the flypaper effect doesn’t present in grant expenditures. The election years significant for grant expenditures where this expenditure will increase in the year of the election . The political concentration significant for grant expenditures, the lower the political concentration, the higher grant expenditures will be. It can be concluded that the flypaper effect get additional stimulus during the election years on grant expenditures, in the board with a low political concentration, grant expenditures will be higher."

"ABSTRAKPengobatan pada pasien malaria rawat inap sebagian menunjukkan hasil yangdiharapkan yaitu sembuhnya penyakit, namun tidak sedikit yang gagal dalammenjalani terapi sehingga meningkatkan lama rawat bahkan dapat berujung padakematian. Oleh sebab itu dibutuhkan upaya dalam mengidentifikasi,menyelesaikan dan mencegah terjadinya masalah terkait obat. Penelitian inibertujuan mengevaluasi perbedaan pengobtan standar dan tidak standar pada hasilterapi pasien malaria rawat inap di RSUD Kabupaten Bangka Tengah Tahun2013. Penelitian ini dilakukan dengan metode kohort retrospektif berdasarkandata rekam medik pasien malaria rawat inap di RSUD Kabupaten Bangka TengahTahun 2013. Data 45 pasien malaria yang mendapat pengobatan standardibandingkan dengan 45 pasien pengobatan tidak standar dianalisis menggunakanchi-square dan regresi logistik multivariat. Pasien malaria rawat inap sebagianbesar menderita malaria tropika (62,22%), tanpa komorbit (88,89%), mendapatobat polifarmasi (88,89%), dirawat selama 1-4 hari (86,67%). Obat antimalariayang terbanyak digunakan adalah kombinasi dehidroartemisisn-piperakuin danprimakuin (44,44%). Masalah terkait obat yang paling banyak ditemui adalahobat tidak tepat (18,45%), durasi obat terlalu tinggi, regimen dosis terlalu sering(18,45%), tidak ada indikasi untuk obat (16,5%). Pengobatan standar tidakberpengaruh terhadap lama rawat (p=0,568) pasien malaria rawat inap di RSUDKabupaten Bangka Tengah. Pengobatan standar (RR= 0,10;CI=0,034-0,318) danadanya komorbiditas (RR=12,11;CI=2,607-56,296)) secara signifikan (p< 0,05)mempengaruhi kejadian masalah terkait obat.

---

ABSTRACTTreatment of malaria patients hospitalized partially shows the expected result is toheal diseases, but others fail to undergo thereby increasing the length of stay caneven lead to death. Therefore, the contribution required to identify, resolve andprevent drug related problems. The purpose of this study was to assess theinfluence of the length of stay and the incidence of drug-related problems in thetreatment of malaria patients hospitalized at the Hospital of Central Bangka Midyear2013. This study was conducted using retrospective cohort based on datafrom medical records of patients hospitalized malaria in Central Bangka RegencyHospital Year 2013. Data of 45 patients who received the standard treatment ofmalaria compared with 45 patients is not standard treatment were analyzed usingchi-square and multivariate logistic regression. Hospitalized malaria patientsmostly suffering from tropical malaria (62,22%), with no comorbidity (88,89%),received medication polypharmacy (88.89%) and length of stay ≤ 4 days(86.67%). Antimalarial drugs most is a combination dehidroartemisin-piperaquineand primaquine (44.44%). Drug related problems, Inappropriate drug (not mostappropriate for indication) (18.45%), Drug dose too high or dosage regime toofrequent (18.45%), No clear indication for drug use (16.5%). The standardtreatment has no effect on length of stay (p = 0.568) malaria patients hospitalizedin hospitals of Central Bangka. Standard treatment (RR= 0,1;CI=0,034-0,318) andcomorbidity (RR=12,11;CI=2,607-56,296) was significantly (p <0, 05) affect theincidence of drug-related problems."